Drexler, B., Passweg, J. R., Tzankov, A., Bigler, M., Theocharides, A. P., Cantoni, N., . . . Skoda, R. C. (2019). The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: Results of phase II study SAKK 33/14. Haematologica.
Citación estilo ChicagoDrexler, Beatrice, et al. "The Sympathomimetic Agonist Mirabegron Did Not Lower JAK2-V617F Allele Burden, but Restored Nestin-positive Cells and Reduced Reticulin Fibrosis in Patients With Myeloproliferative Neoplasms: Results of Phase II Study SAKK 33/14." Haematologica 2019.
Cita MLADrexler, Beatrice, et al. "The Sympathomimetic Agonist Mirabegron Did Not Lower JAK2-V617F Allele Burden, but Restored Nestin-positive Cells and Reduced Reticulin Fibrosis in Patients With Myeloproliferative Neoplasms: Results of Phase II Study SAKK 33/14." Haematologica 2019.